“Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients with Stage I-III Cutaneous Melanoma ”, J of Skin, vol. 8, no. 2, p. s386, Mar. 2024, doi: 10.25251/skin.8.supp.386.